Deals and Financings
CanSino Biologics (HK:6185), a Tianjin vaccine company, rose 58% in its first trading day on the Hong Kong Exchange after staging its $161 million IPO. At the IPO price, CanSino was valued at $617 million; its market capitalization is now $968 million. The company is the seventh China biopharma, and its first vaccine company, to complete an IPO in Hong Kong under the exchange's pre-revenue rules. Of the seven companies, five have now moved higher in price post-IPO, though CanSino's 58% climb is by far the best first-day performance.
Dingdang Medicine Express